Cargando…

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab

INTRODUCTION: Targeted biological therapies for psoriasis have resulted in significant benefits, with therapeutic goals such as clear or almost clear skin accompanied by improvements in health-related quality of life (HRQoL). The objective of this study was to compare the effects of 52 weeks of trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambert, Jo, Hansen, Jes Birger, Sohrt, Anne, Puig, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322208/ https://www.ncbi.nlm.nih.gov/pubmed/33988818 http://dx.doi.org/10.1007/s13555-021-00545-5

Ejemplares similares

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors
por: Kokolakis, Georgios, et al.
Publicado: (2021)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
por: Feldman, Steven R., et al.
Publicado: (2018)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL)
por: Lacour, Jean-Philippe, et al.
Publicado: (2020)

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
por: Pinter, Andreas, et al.
Publicado: (2019)

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Adjusted treatment COMPArisons between guSelkumab and uStekinumab for treatment of moderate‐to‐severe plaque psoriasis: the COMPASS analysis
por: Diels, J., et al.
Publicado: (2020)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
por: Gambardella, Alessio, et al.
Publicado: (2021)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis
por: Kokolakis, Georgios, et al.
Publicado: (2022)

Listeria Meningitis in a Patient With Plaque Psoriasis on Ustekinumab Therapy
por: Roy, Moni, et al.
Publicado: (2022)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Emerging dermatological and systemic applications of ustekinumab: beyond its clinical use in psoriasis
por: Kapoor, Shailendra
Publicado: (2012)

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
por: Bagel, Jerry, et al.
Publicado: (2018)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
por: Choi, Chong Won, et al.
Publicado: (2018)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis
por: Van den Berghe, N., et al.
Publicado: (2019)

Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
por: Harris, Kristina M., et al.
Publicado: (2021)

Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
por: Avgerinou, Georgia, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0uqc3pfa4nnku9sne0dsk4j3p9